### **CLOSING REMARKS**



**Replica** Analytics

AN AETION COMPANY

WHAT WE HAVE LEARNED TODAY

Presented by:




**Dorothee B. Bartels,** Chief Digital Officer, Aetion

#### Synthetic Data Summit 2023




#### Summary: Building on what we heard One topic - many perspectives



# Risk assessments should consider purpose and context of data use.


Always budget for and consult with data privacy experts.






ICO - UK Information Commissioner's office High fidelity data can be used for data augmentation and debiasing data, e.g. in clinical trials and for model training.


Early engagement with MHRA is key when using SD.




#### We know that balancing utility and privacy is key, explainability and adoption - i.e. user centricity - are similar important.



## European data protection laws require deep expertise to ensure compliance - both, for anonymized and synthesized data.




# Synthetic data are essential for extending the use of RWD for research in a privacy conserving manner.




### BfArm (German regulatory body)

Synthetic data allow clinical trial data sharing and enhancing clinical development, incl. simulation and prediction of patients and outcomes.




Utility, privacy, reliability, accuracy, transparency, and validation are important proof points for industry players.

Private-public partnerships can speed-up the development of methods/use cases, and enhance trust.



Different types of data are complex to synthesize and require different methods, e.g. for longitudinal data.

Bias mitigation below 50% is addressable, above 80% it is difficult to compensate for.



#### Thank you for this most interesting and interactive day!

